Israel-based gummy supplement specialist TopGum Industries has completed the acquisition of Island Abbey Nutritionals, a Canada-based CDMO in supplement gummies and lozenges.
TopGum said the acquisition will enhance its manufacturing and technological capabilities, reinforcing its position as a provider of gummies in North America and beyond.
With Island Abbey, TopGum’s annual revenue run-rate is expected to surpass $100m, strengthening its role as a preferred partner to Tier-1 brands and customers globally.
TopGum CEO Eyal Shohat said: “I want to extend my sincere congratulations to everyone who contributed to bringing this important transaction to a successful close.
“This marks a significant step forward for TopGum as we expand our global footprint and capabilities. We look forward to working closely with the Island Abbey team to unlock new opportunities for innovation and growth.”
Founded in 2004, Island Abbey specialises in gummy and lozenge delivery formats for dietary supplements, with a focus on R&D and operational excellence.
The company operates a 65,000ft² facility in Prince Edward Island, equipped with advanced manufacturing technologies like starchless depositing and centre-fill capabilities.
The facility meets high-quality standards, including FDA, NSF, GMP, SQF, and Health Canada certifications.
The acquisition boosts TopGum’s ability to serve North American customers with greater agility and responsiveness, creating an integrated supply chain across two continents.
The combined expertise and capacity will support the company’s mission to deliver high-quality, differentiated gummy supplements.
Island Abbey CEO Dean Williams said: “On behalf of the entire Island Abbey team, I’m thrilled to officially join forces with TopGum.
“We’re excited to bring our expertise, capabilities, and passion for product innovation into this new partnership. Together, we’re well-positioned to accelerate the next chapter of growth for our customers and employees alike.”
